The narcolepsy treatment market is projected to grow from USD 5,301.6 million in 2024 to USD 8,718.3 million by 2034, at a ...

People who live with narcolepsy — about one out of every 2,000 Americans — don’t have many options when it comes to treatment. The milder form of narcolepsy includes symptoms of excessive ...

Narcolepsy Treatment Market Narcolepsy Treatment Global Narcolepsy Treatment Market to Grow at 5.1% CAGR, Reaching USD 8,718.3 Million by 2034. Key Drivers Include Advanced Drugs, Devices, & Gro ...

A n international team of researchers identified over 300 new genetic risk factors associated with depression, offering fresh ...

Among the myriad drugmakers laying out their plans for the future at this year’s J.P. Morgan Healthcare Conference, Takeda ...

Alkermes wants to augment its pipeline with M&A or licensing deals in serious mental illnesses and substance abuse. “I think ...

E-2086 is under clinical development by Eisai and currently in Phase I for Narcolepsy. According to GlobalData, Phase I drugs for Narcolepsy have an 80% phase transition success rate (PTSR) indication ...

Speaking at the JP Morgan Healthcare Conference 2025 yesterday (14 January), Cozadd said: “We’ve got some really exciting ...

The majority of individuals with idiopathic hypersomnia report that their disorder affects their social lives and romantic relationships.

The FDA approves AVDL's Lumryz for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients aged seven years and older with narcolepsy. -- LUMRYZ is the only FDA-approved once ...

Amid a rapidly evolving macroenvironment, Takeda is changing up its R&D priorities and investment strategy. | “There's an ...